Palisade bio (nasdaq: pali) reports year end 2021 financial results and corporate update

Carlsbad, calif., march 18, 2022 (globe newswire) -- palisade bio, inc. (nasdaq: pali) (“palisade” or the “company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients suffering with acute and chronic gastrointestinal (gi) complications, today provides a business update and reports its financial results for the year ended december 31, 2021.
PALI Ratings Summary
PALI Quant Ranking